There's a Lot Riding on the Myriad Case

At the end of October the Biotechnology Industry Organization and the Association of University Technology Managers joined in an amicus brief filed in AMP v. USPTO. (Here's the story on the original District Court finding against Myriad Genetics.) The brief spells out the dire consequences to research and funding in the the biotechnology world should the Federal Curcuit choose not to reverse.